Global gene therapy deals sky-rocketed to nearly $5 bn in 2014

Licensing deals have so far outpaced historical levels, with over $1.8 billion signed in 2015.


(Photo Courtesy:

The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined value rising spectacularly from $122.8 million to $4.9 billion over the same period, representing a forty-fold increase, says research and consulting firm GlobalData.

The company's latest report states that merger and acquisition (M&A) activity is typically low in the gene therapy field, as the technology remains highly experimental and the majority of products are in early-stage clinical development.

Despite this, the impressive growth in the overall deals value for 2014 was boosted primarily by Abbott Laboratories' $2.9 billion acquisition of CFR Pharmaceuticals (CFR), a Chilean biotechnology company developing gene therapeutics for alcoholism and chronic pain.

CFR has a product in its clinic that targets aldehyde dehydrogenase, an enzyme produced in the liver and kidneys aiding alcohol rejection.

Mr Adam Dion, GlobalData's senior industry analyst, says: "Licensing and partnerships, together with capital raisings, have represented the largest number of gene therapy deals struck since 2009. 


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email